Skip to content

Author

Rengina Kefalogianni

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Clinical and economic benefits of bivalent Respiratory syncytial virus prefusion F (RSVpreF) vaccine for prevention of RSV in adults: a cost-effectiveness analysis for Singapore.

RSVpreF vaccination would substantially reduce the clinical and economic burden of RSV among adults in Singapore and be cost-effective under a threshold of 1 ×gross domestic product per capita per QALY gained.

K. Thakkar, A. Shajarizadeh, Nishu Gaind et al. · 0 citations
Open access Sep 2026

Clinical and economic impact of bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination in older adults: a cost-effectiveness analysis for Chile.

BACKGROUND Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in older adults in Chile. Chile's National Immunization Technical Advisory Group (NITAG) recommended RSV vaccination for adults aged ≥60 years with risk factors for severe illness. This study estimated the cost-effectivenes...

Rafael Bolaños, Tomas Eduardo Abbott, A. Shajarizadeh et al. · 0 citations
Open access Aug 2026

Cost-Effectiveness Analysis of Older Adult Vaccination with the Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine in Mexico

Year-round RSVpreF vaccination in Mexico among adults aged 60–99 years could substantially reduce medically attended RSV cases and RSV-related mortality and is projected to be cost-effective, thereby supporting the adoption of preventive strategies to address the growing clinical and economic burden of RSV in Mexico’s...

V. Guajardo, A. Shajarizadeh, Nishu Gaind et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.